• Dentsply Sirona has reported Q1 2026 results showing essentially flat sales of US$880 million year on year but a swing from a US$20 million net profit to a US$10 million net loss, while also advancing its Return-to-Growth plan.
• At the same time, the company launched Smart View – Detect, the first FDA-cleared AI-enabled diagnostic aid for PARL detection in CBCT scans, and expanded its U.S. digital dentistry reach through an enhanced distribution agreement with Atlanta Dental Supply.
• We’ll now examine how the new Smart View – Detect AI capability may reshape Dentsply Sirona’s investment narrative and long-term positioning.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

DENTSPLY SIRONA Investment Narrative Recap

To own Dentsply Sirona, you need to believe its digital and AI investments can eventually offset recent profit volatility and persistent top line softness. Q1 2026’s flat US$880 million sales but swing to a US$10 million net loss keep the near term focus firmly on execution of the Return to Growth plan, while the biggest risk remains that revenue in key categories and regions fails to reaccelerate meaningfully.

Among the latest announcements, Smart View – Detect stands out as most relevant, because it deepens the DS Core ecosystem and reinforces the push into higher value software and imaging workflows. If clinicians adopt the tool at scale, it could gradually support the company’s effort to shift toward more recurring, digitally enabled revenue streams, which sits at the heart of the current catalyst narrative around margin and earnings improvement.

Yet beneath the promise of AI driven dentistry, investors should be aware that persistent revenue weakness in core segments could still...

DENTSPLY SIRONA's narrative projects $3.7 billion revenue and $161.6 million earnings by 2029. This implies fairly flat yearly revenue growth and a $759.6 million earnings increase from -$598.0 million today.

Uncover how DENTSPLY SIRONA's forecasts yield a $14.54 fair value, a 28% upside to its current price.

Exploring Other Perspectives

While consensus leans on digital growth and cost savings, the most cautious analysts saw flattish revenue near US$3.7 billion and only US$108.9 million of earnings, so Q1’s mixed update could either soften or reinforce those more pessimistic views depending on how you weigh execution risk versus innovation momentum.

Explore 3 other fair value estimates on DENTSPLY SIRONA - why the stock might be worth just $14.54!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free DENTSPLY SIRONA research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DENTSPLY SIRONA's overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.